For example, only eight studies assessed treatment with the newer GLP-1 drugs, and the maximum follow-up period in these studies was 12 months after medication stopped
American Diabetes Association: Cardiovascular disease and risk management
In a phase 2 trial of obese subjects, cagrilintide used in different subcutaneous doses once weekly was associated with a mean weight loss of 6-10.8% after 26 weeks, compared with 9.0% with the glucagon-like 1 receptor (GLP-1R) liraglutide (3 mg/d) and 3% with placebo at 26 weeks
Chemogenetic inhibition of DMH LepR neurons led to increased food intake by increasing the number of licking bouts without altering bout length, in contrast to the increased bout duration in DMH GLP-1R neurons, implying that DMH LepR neurons play a role in satiety [48]
Tirzepatide: A dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist, Tirzepatide takes weight management to the next level by enhancing fat metabolism and reducing appetite even further
The wider peptide guides and dosing protocols library covers reconstitution maths, storage handling, and protocol templates across the catalogue, and the skin and pigmentation research category groups MT-II alongside related melanocortin-active compounds for comparative work
